@prefix dcterms: .
@prefix dcat: .
@prefix foaf: .
@prefix xsd: .
@prefix ldp: .
a dcterms:RightsStatement;
"RESTRICTED" .
a dcat:Resource,
dcat:Catalog;
"Swiss Personalized Oncology National Data Stream (SPO-NDS)";
dcterms:title "Swiss Personalized Oncology National Data Stream (SPO-NDS)";
dcat:version "1.0";
"2026-10-16T09:38:16.400543825Z"^^xsd:dateTime;
"2026-10-16T09:38:30.620916429Z"^^xsd:dateTime;
dcterms:conformsTo , ;
dcterms:language ;
;
dcterms:identifier "http://fdp.dcc.sib.swiss/catalog/88f8fde4-aff4-5c05-919c-2edba893bcd7";
dcterms:accessRights ;
dcterms:publisher [ a foaf:Agent;
foaf:name "Swiss Personalized Health Network (SPHN)"
];
dcat:contactPoint ;
,
;
,
, ,
"Cantonal data protection laws";
18;
1558;
dcterms:abstract "The goal of the Swiss Personalized Oncology (SPO)-NDS is to build and extend the existing infrastructure, datasets, and know-how developed over the first 3 years of the Swiss Personalized Oncology SPHN Driver project. The SPO-NDS will aim to consolidate the clinical data acquisition, finalizing the extraction of the core data set at the 5 University Hospitals and at the Swiss Group for Clinical Cancer Research (SAKK), and pursuing the natural language processing applications to enrich the data set. In addition, high value cohorts have been and will be assembled in cancer types treated with immuno-oncology (IO) therapies that will allow comparative immunomics between highly IO sensitive tumors (e.g., melanoma, lung-cancer, triple-negative breast cancer (TNBC)) to less sensitive (e.g., MSI-CRC, hormone receptor-positive breast cancer). Using the momentum of the Tumor Profiler (TuPro) initiative, single-cell and -omics data will now be at the center of the program including NGS, IMC, digital pathology, as well as functional drug screening to drive therapeutic decisions within the existing molecular tumor boards.";
dcterms:isPartOf ;
dcterms:source ,
,
, ;
dcterms:temporal [ a dcterms:PeriodOfTime;
dcat:endDate "2025-12-31"^^xsd:date;
dcat:startDate "2010-01-01"^^xsd:date
];
"SPO-NDS";
"ACTIVE";
[ a foaf:Organization;
"Universitatsspital Basel";
dcterms:identifier ;
foaf:homepage
], [ a foaf:Organization;
"Centre hospitalier universitaire vaudois";
dcterms:identifier ;
foaf:homepage
], [ a foaf:Organization;
"Hopitaux universitaires de Geneve";
dcterms:identifier ;
foaf:homepage
], [ a foaf:Organization;
"Inselspital - Universitatsspital Bern";
dcterms:identifier ;
foaf:homepage
], [ a foaf:Organization;
"Universitatsspital Zurich";
dcterms:identifier ;
foaf:homepage
];
"Clinical Routine";
"Reuse conditions are regulated in the SPO Consortium Agreement and reuse is approved by the Consortium Executive Board. Third parties can apply for reuse.";
"Melanoma-specific criteria: Uveal melanoma (ICD-10 C69)",
"Overall criteria: patients treated for multiple cancers";
[ a foaf:Organization;
"Personalized Health and Related Technologies";
foaf:homepage
], [ a foaf:Organization;
"Swiss Personalized Health Network";
foaf:homepage
];
"Breast cancer-specific criteria: ICD-10 code C50 or text contains ‘mammakarzinom', case insensitive, treated with either CDK inhibitors (ATC codes L01EF) or anti PD-1/PD-L1-based therapies (L01FF) or trastuzumab deruxtecan (L01FD04) or datopotamab deruxtecan (L01FX35) or sacituzumab govitecan (L01FX17) or trastuzuman emtanisne (L01XC14, L01FD03), metastatic",
"CRC-specific criteria: ICD-10 code C18, C19 or C20, or German diagnosis text contains 'Dickdarmkrebs|Krebs des Dickdarms|Coecumkarzinom|Ascendenskarzinom|Transversumkarzinom|Descendenskarzinom|Kolonkarzinom|Sigmakarzinom|Karzinom des rektosigmoidalen Übergangs|Rektumkarzinom|Mastdarmkrebs|Enddarmkrebs', or French diagnosis text contains 'carcinome|cancer|adenoCa|adenoCa' and 'cæcal|caecal|caecum|cæcum|colique|colon|colon|rectal|rectum|sigmoid|sigmoïd', all case insensitive, stage IV (metastatic), treated with any systemic antineoplastic therapy (ATC code L01)",
"Melanoma-specific criteria: ICD-10 code C43 or diagnosis text contains 'melanoma|melanom|melanome', treated with anti-PD-1 based or anti-PDL-1 based therapies",
"NSCLC-specific criteria: note of NSCLC in German diagnosis text, which is one of 'NSCLC|Lungadenom|Lungenadenokarzinom|bronchioloalveolares Karzinom|bronchoalveolares Karzinom|PEC der Lunge|LCNEC', or one of 'bronchial|bronchialkarzinom|bronchus|lunge|lungenkarzinom|lungenkrebs|lungenmalignom|lungentumor|pulmonal|thorakal' together with one of 'adenokarzinom|adenosquamoses karzinom|epidermoidkarzinom|(großzellige|grosszellige) (karzinom|krebs|tumor)|karzinoid|nichtkleinzellige|nichtkleinzellige|nicht-kleinzellige|plattenepithel (karzinom|krebs|tumor)|pleomorphes karzinom|riesenzellkarzinom|Sarkomatoides karzinom|spindelzellkarzinom', or in French diagnosis note, which is one of 'NSCLC|carcinome bronchioloalveolaire|carcinome broncho-alveolaire', or one of 'bronchique|bronche|poumon|pulmonaire|thoracique|lobe |lobaire|lobulaire' together with one of 'adenocarcinome|adenome|carcinome adenosquameux|carcinome epidermoïde|carcinome spinocellulaire|(carcinome|cancer|tumeur) (grandes cellules|cellules geantes|non à petites cellules)|carcinome pleomorphe|carcinome sarcomatoïde|carcinome à cellules fusiformes', all case insensitive and all possibilities entailed by German declension and inflection considered, stage IV (metastatic)",
"Overall criteria: age at first date (incidence datetime) of diagnosis older than 18 years, approval of general consent, treated within the university hospital, biopsy assessed by NGS, date of NGS on or after 1st of January 2015",
"treated with anti-PD1 or anti-PDL1 based therapies";
"Bernd Bodenmiller",
"Olivier Michielin";
[ a foaf:Organization;
"University of Bern";
foaf:homepage
], [ a foaf:Organization;
"Kantonsspital Baselland";
foaf:homepage
], [ a foaf:Organization;
"University of Zurich";
foaf:homepage
], [ a foaf:Organization;
"HES-SO University of Applied Sciences and Arts Western Switzerland";
foaf:homepage
], [ a foaf:Organization;
"ETH Zurich";
foaf:homepage
], [ a foaf:Organization;
"University of Geneva";
foaf:homepage
], [ a foaf:Organization;
"Swiss Group for Clinical Cancer Research";
foaf:homepage
], [ a foaf:Organization;
"EPFL - Swiss Federal Technology Institute of Lausanne";
foaf:homepage
], [ a foaf:Organization;
"University of Lausanne";
foaf:homepage
], [ a foaf:Organization;
"University of Basel";
foaf:homepage
];
"1.51";
"Retrospective Observational Study",
"Prospective Observational Study";
dcterms:issued "2026-10-16T09:38:16.400543825Z"^^xsd:dateTime;
dcterms:modified "2026-10-16T09:38:16.400543825Z"^^xsd:dateTime;
dcat:dataset ,
, ,
, ;
dcat:themeTaxonomy ;
dcat:keyword "SPO-NDS-2024.1", "SPO-NDS-2025.1", "SPO-NDS-catalog";
foaf:page , .
a ;
"Olivier.Michielin@hug.ch" .
a ;
dcterms:identifier "http://fdp.dcc.sib.swiss/catalog/88f8fde4-aff4-5c05-919c-2edba893bcd7" .
"Data Protection Act" .
"Clinical Registry" .
"Human Research Act" .
"Human Research Ordinance" .
"Healthcare Information System" .
"Omics Facility" .
"NCI Thesaurus" .
"Research Laboratory" .
"SPO RDF Schema 2025.1" .
"SPO-NDS 2024.1" .
"SPO-NDS 2025.1" .
;
.
;
.
a ldp:DirectContainer;
dcterms:title "Datasets";
ldp:membershipResource ;
ldp:hasMemberRelation dcat:dataset;
ldp:contains ,
, ,
, .
"Catalog Profile" .